XML 53 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Collaboration and License Agreements - Additional Information (Details) - USD ($)
9 Months Ended
Sep. 10, 2018
Feb. 24, 2016
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Collaboration and License Agreements [Line items]          
Revenue recorded included in deferred revenue     $ 6,400,000    
Deferred revenue     10,767,000   $ 8,436,000
Development and Commercial License Agreement | Servier          
Collaboration and License Agreements [Line items]          
Upfront payment   $ 105,000,000      
Revenue recorded included in deferred revenue     4,400,000 $ 4,300,000  
Deferred revenue     83,800,000   88,600,000
Development or sales-based milestone payments     0 0  
Development and Commercial License Agreement | Servier | Current Liabilities          
Collaboration and License Agreements [Line items]          
Deferred revenue     5,900,000   5,800,000
Development and Commercial License Agreement | Servier | Maximum          
Collaboration and License Agreements [Line items]          
Total payments to be received   1,600,000,000      
Aggregate milestone payments   1,500,000,000      
Development milestone payments   401,300,000      
Commercial milestone payments   $ 1,100,000,000      
Collaboration and License Agreement | Gilead          
Collaboration and License Agreements [Line items]          
Revenue recorded included in deferred revenue     10,000,000 $ 700,000  
Deferred revenue     4,900,000   2,300,000
Development or sales-based milestone payments     $ 0    
Research funding payment term 3 years   3 years    
Semi-annual research funding payments $ 40,000,000        
Collaboration and License Agreement | Gilead | Current Liabilities          
Collaboration and License Agreements [Line items]          
Deferred revenue     $ 4,900,000   $ 2,300,000
Collaboration and License Agreement | Gilead | Maximum          
Collaboration and License Agreements [Line items]          
Development milestone payments 105,000,000        
Commercial milestone payments 340,000,000        
Receivable from research funding 40,000,000        
Development and commercial milestone payments $ 445,000,000